Welcome to our dedicated page for Dassault Systemes news (Ticker: DASTY), a resource for investors and traders seeking the latest updates and insights on Dassault Systemes stock.
Dassault Systèmes SA reports company news centered on its 3DEXPERIENCE platform, virtual twins, and software activity across manufacturing industries, life sciences and healthcare, and infrastructure and cities. Updates commonly cover software revenue, cloud activity, annual run-rate trends, operating cash flow, margin performance, and product themes such as SOLIDWORKS, CENTRIC, 3D UNIV+RSES, and industrial AI.
Company announcements also address shareholder and governance matters, including combined shareholders’ meetings, Universal Registration Document filings with the Autorité des marchés financiers, share repurchase program descriptions, dividend proposals, outstanding share and voting-right declarations, and board leadership changes.
Dassault Systèmes reported Q3 2024 results with total revenue up 4% to €1.46 billion, driven by subscription revenue growth of 8%. The company's operating margin was 29.6% with EPS at €0.29. While MEDIDATA showed sequential improvement and SOLIDWORKS accelerated growth, automotive market contraction in Europe and US affected performance. The company updated its FY24 total revenue growth forecast from 6-8% to 5-7%, while maintaining its diluted EPS target of €1.27-€1.30. Q4 2024 is expected to show revenue growth acceleration to 8% mid-point.
Snam, Europe's leading gas infrastructure operator, is implementing Dassault Systèmes' 3DEXPERIENCE platform to digitally transform its gas network management. The platform will create virtual twins of Snam's gas pipelines, storage sites, and LNG terminals in Italy, along with future assets. This strategic project aims to enhance asset operations, improve structural safety, and reduce emissions through collaborative management and real-time data integration. The implementation will enable Snam to streamline engineering processes and enhance asset effectiveness while supporting its sustainable energy transition goals.
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) has released its declaration of outstanding shares and voting rights as of September 30, 2024. The company reported:
- 1,339,433,323 outstanding shares
- 2,013,172,814 voting rights
The total number of voting rights is calculated based on all outstanding shares, including those with suspended voting rights. Shareholders are advised to refer to Article 223-11 of the General Regulation of the Autorité des marchés financiers for threshold crossing declarations. Such declarations should be sent to Dassault Systèmes' Investor Relations Service.
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) has released its declaration of outstanding shares and voting rights as of August 31, 2024. The company reported:
- Number of outstanding shares: 1,339,313,330
- Number of voting rights: 2,013,085,275
The total voting rights are calculated based on all outstanding shares, including those with suspended voting rights. Shareholders are advised to refer to Article 223-11 of the General Regulation of the Autorité des marchés financiers for threshold crossing declarations.
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) has released its declaration of outstanding shares and voting rights as of July 31, 2024. The company reported a total of 1,339,195,132 outstanding shares and 2,013,093,440 voting rights. This information is provided in compliance with articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers.
The total number of voting rights is calculated based on all outstanding shares, including those with suspended voting rights. Shareholders are advised to refer to Article 223-11 of the General Regulation for guidance on declaring threshold crossings. Such declarations should be sent to Dassault Systèmes' Investor Relations Service.
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) has disclosed its trading in own shares for July 26, 2024, as part of a repurchase program approved by shareholders on May 22, 2024. The company repurchased a total of 2,000,000 ordinary shares across various markets:
- XPAR: 618,046 shares at an average price of €34.7740
- DXE: 1,321,954 shares at an average price of €34.8243
- TQE: 20,000 shares at an average price of €34.7913
- AQE: 40,000 shares at an average price of €34.8891
Detailed transaction information is available on Dassault Systèmes' investor relations website. This disclosure is part of the company's commitment to transparency in its share repurchase activities.
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) has announced the availability and filing of its 2024 Half-Year Financial Report with the French Autorité des marchés financiers. The report, which includes half-year condensed consolidated financial statements prepared in accordance with IFRS standards, covers the period up to June 30, 2024. The report is now accessible to the public on Dassault Systèmes' website at https://investor.3ds.com/regulated-information/periodic-information. Hard copies can also be obtained upon request at the company's headquarters in Vélizy-Villacoublay, France.
Dassault Systèmes (DASTY) reported its Q2 2024 results, with total revenue growing 4% to €1.496 billion and non-IFRS diluted EPS up 8% to €0.30. For the first half of 2024, total revenue increased 5% with subscription revenue up 9%. The operating margin was 30.5%, and diluted EPS grew 10% to €0.60. 3DEXPERIENCE software revenue grew by 23% y/y in H1 despite observed volatility in customer decisions in June. The company updated its full-year outlook, now expecting total and software revenue growth of 6% to 8% and diluted EPS growth between 8% and 11%. Dassault Systèmes maintains a strong pipeline and expects to close the majority of delayed deals this year.
Medidata, a Dassault Systèmes brand, announced that Eisai Inc. has selected its AI-driven Clinical Data Studio to enhance clinical trial efficiency and patient experience. The solution aims to accelerate data review and reconciliation by 80%. Eisai will use this innovative data experience to gain better control over clinical data, execute complex trials, and improve patient experience.
Clinical Data Studio, powered by the Medidata Platform, centralizes management of all data sources, improving data reliability across the clinical trial ecosystem. It integrates data from Medidata and non-Medidata sources, streamlining the import process and enabling automatic validation. The AI-driven solution offers up to 80% faster data review and provides a comprehensive view of patient data for concurrent review, visualization, and action.
Dassault Systèmes has announced its preliminary non-IFRS unaudited financial results for Q2 2024, revealing a total revenue of approximately €1.495 billion, marking a 4% year-over-year increase but falling short of the company's €1.525-1.555 billion target. The revenue shortfall is mainly attributed to €30 million in transaction delays. Despite this, diluted EPS is estimated at €0.30, aligning with the company's guidance range of €0.30-0.31. In light of these results and ongoing customer decision-making volatility, Dassault Systèmes has updated its full-year 2024 guidance, forecasting total revenue growth of 6-8% and diluted EPS growth of 8-11%, down from previous projections of 8-10% and 10-12%, respectively. The company will hold a conference call to discuss these results and its financial outlook in detail.